HSE Approves Skyclarys (Omaveloxolone) for Friedreich’s Ataxia

On 25 August 2026 the HSE Senior Management Team approved the reimbursement of omaveloxolone (Skyclarys®, Biogen) for patients with Friedreich’s Ataxia, a rare progressive neurological condition. The decision followed a substantial reduction in the asking price by Biogen, confirmed by HSE Chief Clinical Officer Dr Colm Henry on RTÉ. The final price is commercially sensitive […]

Prescribed List Update — New Medicines from 1 September 2026

Social Security Minister Elaine Millar approved changes to Jersey’s Prescribed List with effect from 1 September 2026, following recommendations from the Pharmaceutical Benefit Advisory Committee. The Jersey Evening Post reported the changes carry a combined annual cost of £105,000 to the Health Insurance Fund. New additions include: fezolinetant (moderate to severe menopausal vasomotor symptoms); isotretinoin (severe acne); […]